Literature DB >> 9486491

Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD.

J Grimm1, W Zeller, A R Zander.   

Abstract

Acute GVHD (aGVHD) is one of the major problems after allogeneic BMT. The diagnosis of aGVHD is difficult to establish, relying mainly on clinical evaluations and symptoms of aGVHD, often resembling those of organ toxicity, infection or drug rash. In 21 patients after BMT several serum cytokine levels (soluble interleukin-2 receptor (sIL-2R), sTNF-R, SCF, IL-6, IL-8, G-SCF and ICAM-1) were determined in order to evaluate their value as an indicator for aGVHD. The maximum levels of sIL-2R (and none of the other evaluated cytokines) correlated significantly (r = 0.8, P = 0.008) with the severity of aGVHD. We also found a significant correlation between the day of engraftment (neutrophil count >0.5 x 10(9)/l) and the severity of aGVHD (r = 0.5, P = 0.03): engraftment was earlier in patients without aGVHD (median of day 11) than in those with aGVHD (median of day 18). No correlation between sIL-2R and fever or organ toxicity could be found. Our data suggest that the sIL-2R level might be an indicator for aGVHD, reflecting the severity of the disease. In patients with late engraftment the risk of aGVHD seems to be increased, therefore these patients especially should be monitored closely, possibly using sIL-2R levels.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9486491     DOI: 10.1038/sj.bmt.1701041

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  14 in total

1.  [Cutaneous graft-versus-host disease].

Authors:  S Karrer
Journal:  Hautarzt       Date:  2003-05       Impact factor: 0.751

Review 2.  Genomic and proteomic analysis of allogeneic hematopoietic cell transplant outcome. Seeking greater understanding the pathogenesis of GVHD and mortality.

Authors:  John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

Review 3.  Advances in interleukin 2 receptor targeted treatment.

Authors:  J C Morris; T A Waldmann
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 4.  Graft-versus-host disease biomarkers: omics and personalized medicine.

Authors:  Sophie Paczesny; Nisha Raiker; Sam Brooks; Christy Mumaw
Journal:  Int J Hematol       Date:  2013-09       Impact factor: 2.490

5.  A novel soluble form of Tim-3 associated with severe graft-versus-host disease.

Authors:  John A Hansen; Samir M Hanash; Laura Tabellini; Chris Baik; Richard L Lawler; Bryan M Grogan; Barry Storer; Alice Chin; Melissa Johnson; Chee-Hong Wong; Qing Zhang; Paul J Martin; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2013-06-17       Impact factor: 5.742

6.  Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.

Authors:  Bin Xiao; Yu Wang; Wei Li; Megan Baker; Jian Guo; Kelly Corbet; Ephraim L Tsalik; Qi-Jing Li; Scott M Palmer; Christopher W Woods; Zhiguo Li; Nelson J Chao; You-Wen He
Journal:  Blood       Date:  2013-09-16       Impact factor: 22.113

Review 7.  Plasma biomarkers in graft-versus-host disease: a new era?

Authors:  Sophie Paczesny; John E Levine; Thomas M Braun; James L M Ferrara
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

8.  Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.

Authors:  Hisaki Fujii; Geoff Cuvelier; Kevin She; Soudabeh Aslanian; Hiromi Shimizu; Amina Kariminia; Mark Krailo; Zhengjia Chen; Rob McMaster; Axel Bergman; Frederick Goldman; Stephen A Grupp; Donna A Wall; Andrew L Gilman; Kirk R Schultz
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

9.  A biomarker panel for acute graft-versus-host disease.

Authors:  Sophie Paczesny; Oleg I Krijanovski; Thomas M Braun; Sung W Choi; Shawn G Clouthier; Rork Kuick; David E Misek; Kenneth R Cooke; Carrie L Kitko; Angela Weyand; Daniel Bickley; Dawn Jones; Joel Whitfield; Pavan Reddy; John E Levine; Samir M Hanash; James L M Ferrara
Journal:  Blood       Date:  2008-10-02       Impact factor: 22.113

10.  Soluble interleukin-2 receptor level on day 7 as a predictor of graft-versus-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning.

Authors:  Katsuji Kaida; Kazuhiro Ikegame; Junko Ikemoto; Rie Murata; Reiko Irie; Satoshi Yoshihara; Shinichi Ishii; Masaya Okada; Takayuki Inoue; Hiroya Tamaki; Toshihiro Soma; Yoshihiro Fujimori; Shunro Kai; Hiroyasu Ogawa
Journal:  Int J Hematol       Date:  2014-03-06       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.